PMID- 33155868
OWN - NLM
STAT- MEDLINE
DCOM- 20211105
LR  - 20211105
IS  - 1557-8518 (Electronic)
IS  - 1540-4196 (Linking)
VI  - 19
IP  - 2
DP  - 2021 Mar
TI  - Association of Sacubitril/Valsartan with Metabolic Parameters in Patients with 
      Reduced Ejection Fraction Heart Failure at a Multidisciplinary Clinic.
PG  - 115-118
LID - 10.1089/met.2020.0100 [doi]
AB  - Background: Sacubitril/valsartan was approved for New York Heart Association 
      (NYHA) class II-IV heart failure with reduced ejection fraction (HFrEF) in 2015, 
      based on the results of the PARADIGM-HF trial, which showed a reduction in 
      cardiovascular (CV) death and heart failure hospitalization, compared with 
      enalapril. A subsequent subgroup analysis of the trial showed glycemic 
      improvement for patients on sacubitril/valsartan compared with those on 
      enalapril. Methods: This was a retrospective observational study at the Loma 
      Linda University (LLU) International Heart Institute (IHI). The aim was to 
      evaluate the association of sacubitril/valsartan with glycemic index and other 
      metabolic parameters, including change in hemoglobin A1C (HbA1C), blood pressure 
      (BP), ejection fraction (EF), body weight, and lipid profile from baseline and at 
      3, 6, and 12 months. The rates of CV-related hospitalizations and total 
      hospitalizations were also assessed. Results: The change in mean HbA1C from 
      baseline was not significantly different at 1 year (P = 0.993). The mean EF was 
      significantly higher and the mean diastolic BP was significantly lowered. Body 
      weight and lipid parameters remained unchanged. Both the rates of CV-related 
      hospitalizations and total hospitalizations were significantly lowered. For the 
      prespecified subgroup analysis of diabetic HFrEF patients, the mean HbA1C was 
      nonsignificant at 12 months (mean difference -0.48, P = 0.993). Conclusion: A 
      non-significant reduction in HbA1C was associated in HFrEF patients with diabetes 
      mellitus. Large randomized trials are needed to confirm our findings regarding 
      the potential metabolic benefits of sacubitril/valsartan.
FAU - Ryu, Rachel
AU  - Ryu R
AD  - Department of Pharmacy Practice and Administration, Western University College of 
      Pharmacy, Pomona, California, USA.
FAU - Tran, Huyentran
AU  - Tran H
AD  - Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma 
      Linda, California, USA.
FAU - Bahjri, Khaled
AU  - Bahjri K
AD  - Department of Pharmaceutical and Administrative Sciences, Loma Linda University 
      School of Pharmacy, Loma Linda, California, USA.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20201105
PL  - United States
TA  - Metab Syndr Relat Disord
JT  - Metabolic syndrome and related disorders
JID - 101150318
RN  - 0 (Aminobutyrates)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 80M03YXJ7I (Valsartan)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
MH  - Aged
MH  - Aminobutyrates/*therapeutic use
MH  - Biphenyl Compounds/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - California/epidemiology
MH  - Drug Combinations
MH  - Female
MH  - Heart Failure/*drug therapy/epidemiology/*metabolism/physiopathology
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Interdisciplinary Communication
MH  - Male
MH  - Middle Aged
MH  - Patient Care Team
MH  - Retrospective Studies
MH  - Stroke Volume/physiology
MH  - Treatment Outcome
MH  - Valsartan/*therapeutic use
MH  - Ventricular Dysfunction, Left/drug 
      therapy/epidemiology/metabolism/physiopathology
OTO - NOTNLM
OT  - blood glucose
OT  - diabetes mellitus
OT  - heart failure
OT  - hemoglobin A1C
OT  - pharmacists
OT  - type 2
EDAT- 2020/11/07 06:00
MHDA- 2021/11/06 06:00
CRDT- 2020/11/06 12:10
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/11/06 06:00 [medline]
PHST- 2020/11/06 12:10 [entrez]
AID - 10.1089/met.2020.0100 [doi]
PST - ppublish
SO  - Metab Syndr Relat Disord. 2021 Mar;19(2):115-118. doi: 10.1089/met.2020.0100. 
      Epub 2020 Nov 5.